Literature in Oncology: Treatment Assessment
d'Amico A.
Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy.
Radiol Med. 2014 Aug 26.
Pasqual EM, Bertozzi S, Bacchetti S, Londero AP, Basso SM, Santeufemia DA, Lo Re G, Lumachi F.
Preoperative assessment of peritoneal carcinomatosis in patients undergoing hyperthermic intraperitoneal chemotherapy following cytoreductive surgery.
Anticancer Res. 2014 May;34(5):2363-8.
Klumpp B, Schwenzer NF, Gatidis S, Koenigsrainer I, Koenigsrainer A, Beckert S, Mueller M, Claussen CD, Pfannenberg C.
Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
Rofo. 2014 Apr;186(4):359-66.
Jadvar H, Colletti PM.
Competitive advantage of PET/MRI.
Eur J Radiol. 2014 Jan;83(1):84-94.
Walker-Samuel S, Ramasawmy R, Torrealdea F, Rega M, Rajkumar V, Johnson SP, Richardson S, Gonçalves M, Parkes HG, Arstad E, Thomas DL, Pedley RB, Lythgoe MF, Golay X.
In vivo imaging of glucose uptake and metabolism in tumors.
Nat Med. 2013 Aug;19(8):1067-72.
Abdoli M, Dierckx RA, Zaidi H.
Contourlet-based active contour model for PET image segmentation.
Med Phys. 2013 Aug;40(8):082507.
Cho O, Chun M, Oh YT, Kim MH, Park HJ, Heo JS, Noh OK.
Can initial diagnostic PET-CT aid to localize tumor bed in breast cancer radiotherapy: feasibility study using deformable image registration.
Radiat Oncol. 2013 Jul 3;8:163.
Schaefer A, Kim YJ, Kremp S, Mai S, Fleckenstein J, Bohnenberger H, Schäfers HJ, Kuhnigk JM, Bohle RM, Rübe C, Kirsch CM, Grgic A.
PET-based delineation of tumour volumes in lung cancer: comparison with pathological findings.
Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1233-44.
Xu GZ, Li CY, Zhao L, He ZY.
Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis.
Ann Oncol. 2013 Jan;24(1):96-101.
Xu G, Zhao L, He Z.
Performance of whole-body PET/CT for the detection of distant malignancies in various cancers: a systematic review and meta-analysis.
J Nucl Med. 2012 Dec;53(12):1847-54.
Muzi M, O'Sullivan F, Mankoff DA, Doot RK, Pierce LA, Kurland BF, Linden HM, Kinahan PE.
Quantitative assessment of dynamic PET imaging data in cancer imaging.
Magn Reson Imaging. 2012 Nov;30(9):1203-15.
Kitajima K, Ueno Y, Suzuki K, Kita M, Ebina Y, Yamada H, Senda M, Maeda T, Sugimura K.
Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT scans for diagnosing ovarian cancer recurrence.
Eur J Radiol. 2012 Nov;81(11):3557-62.
Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS.
Promise and pitfalls of quantitative imaging in oncology clinical trials.
Magn Reson Imaging. 2012 Nov;30(9):1301-12.
Samarin A, Burger C, Wollenweber SD, Crook DW, Burger IA, Schmid DT, von Schulthess GK, Kuhn FP.
PET/MR imaging of bone lesions--implications for PET quantification from imperfect attenuation correction.
Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1154-60.
Choi BB, Kim SH, Kang BJ, Lee JH, Song BJ, Jeong SH, Yim HW.
Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma.
World J Surg Oncol. 2012 Jun 28;10:126.
Greenspan RL, Suprenant V, Atem F.
Visualization of distal spinal cord on F-18 FDG PET/CT.
Clin Nucl Med. 2012 Feb;37(2):137-41.
Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D.
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation.
J Nucl Med. 2011 Nov;52(11):1690-7.
Zaidi H, El Naqa I.
PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques.
Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2165-87.
Rodríguez N, Sanz X, Trampal C, Foro P, Reig A, Lacruz M, Membrive I, Lozano J, Quera J, Algara M.
18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):659-66.
Gregoire V, Chiti A.
PET in radiotherapy planning: particularly exquisite test or pending and experimental tool?
Radiother Oncol. 2010 Sep;96(3):275-6.
Chung HH, Nam BH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB.
Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer.
Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1467-73.
Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ.
Methodological considerations in quantification of oncological FDG PET studies.
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1408-25.
Goethals I, Hanssens S, Kortbeek K, Smeets P, Van Belle S, Ham H.
Support for Warburg's hypothesis using dynamic (18)F-FDG PET in oncology.
Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):833.
Wang H, Vees H, Miralbell R, Wissmeyer M, Steiner C, Ratib O, Senthamizhchelvan S, Zaidi H.
18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer.
Radiother Oncol. 2009 Nov;93(2):220-5.
Mankoff DA, Dehdashti F.
Imaging tumor phenotype: 1 plus 1 is more than 2.
J Nucl Med. 2009 Oct;50(10):1567-9.
Grimberg H, Levin G, Shirvan A, Cohen A, Yogev-Falach M, Reshef A, Ziv I.
Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis.
Apoptosis. 2009 Mar;14(3):257-67.
Wu AM.
Antibodies and antimatter: the resurgence of immuno-PET.
J Nucl Med. 2009 Jan;50(1):2-5.
Blankenberg FG.
In vivo detection of apoptosis.
J Nucl Med. 2008 Jun;49 Suppl 2:81S-95S.
Pichler BJ, Judenhofer MS, Wehrl HF.
PET/MRI hybrid imaging: devices and initial results.
Eur Radiol. 2008 Jun;18(6):1077-86.
Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, Gown A, Link JM, Tewson T, Krohn KA.
Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
J Nucl Med. 2008 Mar;49(3):367-74.
Urvi Joshi, Pieter G. H. M. Raijmakers, Ingrid I. Riphagen, Gerrit J. J. Teule, Arthur van Lingen, Otto S. Hoekstra
Attenuation-Corrected vs. Nonattenuation-Corrected 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography in Oncology, A Systematic Review
Mol Imaging Biol. 2007 May; 9(3): 99–105.
Krug B, Pirson AS, Crott R, Vander Borght T.
Is a methodology available that accurately measures the cost of an FDG-PET study?
Eur J Nucl Med Mol Imaging. 2007 May;34(5):625-7.
Grills IS, Yan D, Black QC, Wong CY, Martinez AA, Kestin LL.
Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):709-19.
Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight AE, Macapinlac HA, Podoloff DA, Chasen M.Even-Sapir E.
Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation.
AJR Am J Roentgenol. 2006 Feb;186(2):308-19.
van Baardwijk A, de Jong J, Arens A, Thimister P, Verseput G, Kremer B, Lambin P.
False-positive FDG-PET scan due to brown tumours.
Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):393-4.
Song Y, Chan M, Burman C, Cann D.
Inter-modality variation in gross tumor volume delineation in 18FDG-PET guided IMRT treatment planning for lung cancer.
Conf Proc IEEE Eng Med Biol Soc. 2006;1:3803-6.
Gorospe L, Raman S, Echeveste J, Avril N, Herrero Y, Herna Ndez S.
Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients.
Nucl Med Commun. 2005 Aug;26(8):671-87.
Abstract